John Armitage's Egerton Capital sold its entire Carpenter Technology Corp (CRS) position in 2026 Q2, according to the 13F-HR filed with the SEC on July 21, 2026. The prior filing listed 1.33M shares worth about $524.6M, 5.82% of the portfolio; the 2026 Q2 filing lists none. CRS had been in the portfolio for about 1 year, since the quarter ended March 31, 2025.
What did the 2026 Q2 filing report for CRS?
As of June 30, 2026, from the 13F-HR filed July 21, 2026.
| Before | After | |
|---|---|---|
| Shares | 1.33M | 0 |
| Reported value | $524.6M | $0 |
| Portfolio weight | 5.82% | 0% |
| Held since | 2025 Q1 | sold out in 2026 Q2 |
| Quarters held | 5 |
What did John Armitage sell?
John Armitage sold 1.33M shares of CRS between the quarter ended March 31, 2026 and June 30, 2026. The CRS exit was the largest of the quarter's 29 position changes by percent change to portfolio.
Where does CRS sit in the John Armitage portfolio?
Before the sale, CRS carried 5.82% of the John Armitage portfolio, above the fund's average stock position of 4%. The largest stock position is V at 14.13%. Next come GOOG at 11.24% and APH at 8.29%. The three largest stocks together are 33.66% of the book. Across the 2026 Q2 portfolio, John Armitage reported 23 stock positions, with 5 opened and 6 closed. The total portfolio value is about $10.4B, up 15% from the prior quarter.
How long has John Armitage held CRS?
John Armitage held CRS for about 1 year, from the quarter ended March 31, 2025 to March 31, 2026. The weight peaked at 5.82% in 2026 Q1. Last quarter the fund had already cut the position by 14%, so the exit finishes a two-quarter unwind. Every reported trade is on the John Armitage CRS trade history page.
Did other funds buy or sell CRS in 2026 Q2?
Among the other tracked funds that had filed for 2026 Q2 as of July 21, 2026, 3 still hold CRS. The largest sellers were Stephen Mandel, Daniel Loeb and Polen Capital Management. Every tracked holder of CRS is on the CRS ownership page.
FAQ
How many CRS shares did John Armitage sell?
John Armitage sold all 1.33M shares of CRS it reported a quarter earlier, worth about $524.6M.
When did John Armitage first buy CRS?
John Armitage first reported CRS in the quarter ended March 31, 2025.
How much of the John Armitage portfolio was CRS?
CRS was 5.82% of the John Armitage portfolio at the prior quarter-end, and 0% after the sale.
Did other funds sell CRS in 2026 Q2?
No other tracked fund sold out of CRS in 2026 Q2, but 3 trimmed it; 3 still hold it.